Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 4Barrett Esophagus 4Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 2Mouth Neoplasms 2Uterine Neoplasms 1Oral Lesions 1Neoplasms, Squamous Cell 1Mouth Diseases 1Malignant Neoplasms of Female Genital Organs 1Laryngeal Diseases 1Head and Neck Neoplasms 1Gastroesophageal Reflux 1Endometrial Neoplasms 1Colonic Polyps 1Carcinoma, Squamous Cell 1Carcinoma in Situ 1

Interventions

Paclitaxel 95Carboplatin 76pembrolizumab 72Cisplatin 28Bevacizumab 27Letrozole 22Radiotherapy 21Doxorubicin 21Megestrol Acetate 20lenvatinib 19olaparib 18Taxes 17Docetaxel 17Nivolumab 16Specimen Handling 15Metformin 15dostarlimab 14Magnetic Resonance Spectroscopy 14Gemcitabine 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11Biopsy 11temsirolimus 10abemaciclib 10atezolizumab 9Radiation 9Early Intervention, Educational 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endometrial Neoplasms × Proflavine × Clear all
NCT02095847 2015-04-08

High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡